265,981 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 265,981 shares of the company’s stock, valued at approximately $8,110,000. Vestmark Advisory Solutions Inc. owned 0.30% of Intellia Therapeutics as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its holdings in shares of Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after purchasing an additional 1,463,820 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Intellia Therapeutics by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock valued at $111,312,000 after acquiring an additional 125,639 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after acquiring an additional 36,630 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of Intellia Therapeutics by 13.8% during the fourth quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after acquiring an additional 244,722 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB raised its holdings in shares of Intellia Therapeutics by 1,600.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock worth $26,877,000 after acquiring an additional 800,000 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. Wolfe Research started coverage on shares of Intellia Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Wedbush restated a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Insider Activity at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Price Performance

NTLA stock traded up $0.33 on Friday, reaching $23.60. 1,294,988 shares of the company were exchanged, compared to its average volume of 1,217,743. The firm has a market capitalization of $2.28 billion, a PE ratio of -4.36 and a beta of 1.85. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $47.48. The stock’s fifty day moving average price is $26.06 and its 200 day moving average price is $27.30.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The company had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same quarter in the previous year, the firm posted ($1.40) EPS. As a group, research analysts expect that Intellia Therapeutics, Inc. will post -5.57 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.